trial

Effect of Add-on Citalopram to Risperidone on Negative Symptoms in Schizophrenia

NCTId NCT00893256
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 48 (actual)
Sponsored by National Institute of Mental Health and Neuro Sciences, India
Primary completion 2007-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
48 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2004-12
Primary completion
2007-09
Eligibility
ALL · 17 Years · 50 Years

Interventions & indications

Drugs
RisperidoneCitalopram

Sponsors

National Institute of Mental Health and Neuro Sciences, IndiaLead Sponsor

Investigators

1
John W. Newcomer, M.D.Principal Investigator

Sites

1 total
Bangalore, India

Facts & assertions

4 sourced
Enrollment
48
Phase
PHASE4
Primary Completion Date
2007-09
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
Citalopram
drug
lead_sponsor
National Institute of Mental Health and Neuro Sciences, India
company
indication
Schizophrenia
indication
Schizophrenia
indication
Negative Symptoms
indication
investigator
John W. Newcomer, M.D.
person